1. Home
  2. ANAB vs PD Comparison

ANAB vs PD Comparison

Compare ANAB & PD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ANAB

AnaptysBio Inc.

HOLD

Current Price

$49.06

Market Cap

1.2B

Sector

Health Care

ML Signal

HOLD

Logo PagerDuty Inc.

PD

PagerDuty Inc.

HOLD

Current Price

$12.92

Market Cap

1.2B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
ANAB
PD
Founded
2005
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Computer Software: Prepackaged Software
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.2B
IPO Year
2017
2019

Fundamental Metrics

Financial Performance
Metric
ANAB
PD
Price
$49.06
$12.92
Analyst Decision
Buy
Buy
Analyst Count
11
10
Target Price
$59.90
$17.70
AVG Volume (30 Days)
503.4K
3.2M
Earning Date
11-04-2025
11-25-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
1.63
Revenue
$169,467,000.00
$489,207,000.00
Revenue This Year
$135.45
$8.21
Revenue Next Year
N/A
$4.33
P/E Ratio
N/A
$7.96
Revenue Growth
196.42
7.01
52 Week Low
$12.21
$11.13
52 Week High
$48.44
$20.00

Technical Indicators

Market Signals
Indicator
ANAB
PD
Relative Strength Index (RSI) 76.21 42.63
Support Level $43.92 $12.55
Resistance Level $47.86 $13.24
Average True Range (ATR) 2.33 0.36
MACD 0.19 0.14
Stochastic Oscillator 98.35 79.71

Price Performance

Historical Comparison
ANAB
PD

About ANAB AnaptysBio Inc.

AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).

About PD PagerDuty Inc.

PagerDuty Inc is a digital operations management platform that manages urgent and mission-critical work for a modern, digital business. Its PagerDuty Operations Cloud combines artificial intelligence (AI) operations (AIOps), automation, customer service operations, and incident management with a generative AI assistant to create a flexible, resilient, and scalable platform to protect revenue and improve customer experience, improve operational efficiency, and mitigate the risk of operational failures. The company generates revenue predominantly from cloud-hosted software subscription fees and term-license software subscription fees. Geographically, the firm derives a majority of its revenue from the United States and the rest from International markets.

Share on Social Networks: